IL275077B2 - Dosing regimens for mobilization of hematopoietic stem and progenitor cells. - Google Patents

Dosing regimens for mobilization of hematopoietic stem and progenitor cells.

Info

Publication number
IL275077B2
IL275077B2 IL275077A IL27507720A IL275077B2 IL 275077 B2 IL275077 B2 IL 275077B2 IL 275077 A IL275077 A IL 275077A IL 27507720 A IL27507720 A IL 27507720A IL 275077 B2 IL275077 B2 IL 275077B2
Authority
IL
Israel
Prior art keywords
cells
donor
fold
per day
cxcr2 agonist
Prior art date
Application number
IL275077A
Other languages
English (en)
Hebrew (he)
Other versions
IL275077A (en
IL275077B1 (en
Inventor
Dwight Morrow
Anthony Boitano
Patrick C Falahee
Michael P Cooke
Kevin A Goncalves
Original Assignee
Magenta Therapeutics Inc
Ensoma Inc
Dwight Morrow
Anthony Boitano
Patrick C Falahee
Michael P Cooke
Kevin A Goncalves
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US15/834,017 external-priority patent/US10058573B1/en
Application filed by Magenta Therapeutics Inc, Ensoma Inc, Dwight Morrow, Anthony Boitano, Patrick C Falahee, Michael P Cooke, Kevin A Goncalves filed Critical Magenta Therapeutics Inc
Publication of IL275077A publication Critical patent/IL275077A/en
Publication of IL275077B1 publication Critical patent/IL275077B1/en
Publication of IL275077B2 publication Critical patent/IL275077B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/599—Cell markers; Cell surface determinants with CD designations not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/521—Chemokines
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Obesity (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
IL275077A 2017-12-06 2018-12-06 Dosing regimens for mobilization of hematopoietic stem and progenitor cells. IL275077B2 (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US15/834,017 US10058573B1 (en) 2017-12-06 2017-12-06 Dosing regimens for the mobilization of hematopoietic stem cells
US201762596056P 2017-12-07 2017-12-07
US16/101,676 US20190167726A1 (en) 2017-12-06 2018-08-13 Dosing Regimens for the Mobilization of Hematopoietic Stem Cells
US201862753656P 2018-10-31 2018-10-31
US201862773954P 2018-11-30 2018-11-30
PCT/US2018/064335 WO2019113375A2 (fr) 2017-12-06 2018-12-06 Régimes posologiques pour la mobilisation de cellules souches et progénitrices hématopoïétiques

Publications (3)

Publication Number Publication Date
IL275077A IL275077A (en) 2020-07-30
IL275077B1 IL275077B1 (en) 2024-10-01
IL275077B2 true IL275077B2 (en) 2025-02-01

Family

ID=66749948

Family Applications (2)

Application Number Title Priority Date Filing Date
IL275077A IL275077B2 (en) 2017-12-06 2018-12-06 Dosing regimens for mobilization of hematopoietic stem and progenitor cells.
IL315735A IL315735A (en) 2017-12-06 2018-12-06 Dosing Regimens for the Mobilization of Hematopoietic Stem and Progenitor Cells

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL315735A IL315735A (en) 2017-12-06 2018-12-06 Dosing Regimens for the Mobilization of Hematopoietic Stem and Progenitor Cells

Country Status (12)

Country Link
EP (1) EP3720494A2 (fr)
JP (2) JP2021505172A (fr)
KR (1) KR20200096942A (fr)
CN (1) CN111712262A (fr)
AU (1) AU2018378804B2 (fr)
BR (1) BR112020011186A2 (fr)
CA (1) CA3083783A1 (fr)
CO (1) CO2020007275A2 (fr)
IL (2) IL275077B2 (fr)
MX (2) MX2020005878A (fr)
SG (1) SG11202004913TA (fr)
WO (1) WO2019113375A2 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11260079B2 (en) 2017-12-06 2022-03-01 Magenta Therapeutics, Inc. Dosing regimens for the mobilization of hematopoietic stem and progenitor cells
EP4051298A1 (fr) * 2019-11-01 2022-09-07 Magenta Therapeutics, Inc. Schémas posologiques pour la mobilisation de cellules souches et progénitrices hématopoïétiques
EP4143302A1 (fr) * 2020-04-27 2023-03-08 Magenta Therapeutics, Inc. Méthodes et compositions pour la transduction de cellules souches et progénitrices hématopoïétiques in vivo
EP4308694A1 (fr) * 2021-03-16 2024-01-24 Magenta Therapeutics, Inc. Schémas posologiques pour la mobilisation des cellules souches hématopoïétiques en vue d'une greffe de cellules souches chez les patients atteints de myélome multiple
EP4536239A1 (fr) * 2022-06-10 2025-04-16 GPCR Therapeutics, Inc. Inhibiteurs de gpcr et leurs utilisations

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005000333A1 (fr) * 2003-06-05 2005-01-06 Anormed Inc. Procedes de mobilisation de cellules progenitrices/souches
US20060035829A1 (en) * 2004-08-13 2006-02-16 Anormed Inc. Chemokine combinations to mobilize progenitor/stem cells
WO2007047882A2 (fr) * 2005-10-18 2007-04-26 Caritas St. Elizabeth Medical Center Of Boston, Inc. Combinaison d'un antagoniste cxcr4 et d'un morphogene pour l'accroissement de l'angiogenese
WO2008017025A2 (fr) * 2006-08-02 2008-02-07 Genzyme Corporation Thérapie combinée
WO2008019371A1 (fr) * 2006-08-07 2008-02-14 Genzyme Corporation Thérapie combinée
WO2017147610A1 (fr) * 2016-02-26 2017-08-31 President And Fellows Of Harvard College Cellules souches hématopoïétiques à haut potentiel de prise de greffe

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4873191A (en) 1981-06-12 1989-10-10 Ohio University Genetic transformation of zygotes
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5233044A (en) 1989-06-08 1993-08-03 Millipore Corporation Active esters for solid phase peptide synthesis
US5413923A (en) 1989-07-25 1995-05-09 Cell Genesys, Inc. Homologous recombination for universal donor cells and chimeric mammalian hosts
US5021409A (en) 1989-12-21 1991-06-04 Johnson Matthey Plc Antiviral cyclic polyamines
DK0463151T3 (da) 1990-01-12 1996-07-01 Cell Genesys Inc Frembringelse af xenogene antistoffer
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
JP2938569B2 (ja) 1990-08-29 1999-08-23 ジェンファーム インターナショナル，インコーポレイティド 異種免疫グロブリンを作る方法及びトランスジェニックマウス
DE69233782D1 (de) 1991-12-02 2010-05-20 Medical Res Council Herstellung von Autoantikörpern auf Phagenoberflächen ausgehend von Antikörpersegmentbibliotheken
GB9126677D0 (en) 1991-12-16 1992-02-12 Johnson Matthey Plc Improvements in chemical compounds
EP0713495B1 (fr) 1993-06-08 2003-11-05 Smithkline Beecham Corporation Procedes pour ameliorer la bioactivite de chimiokines
US6447766B1 (en) 1993-06-08 2002-09-10 Smithkline Beecham Corporation Method of mobilizing hematopoietic stem cells
GB9400411D0 (en) 1994-01-11 1994-03-09 Johnson Matthey Plc Improvements in chemical compounds
DE69637481T2 (de) 1995-04-27 2009-04-09 Amgen Fremont Inc. Aus immunisierten Xenomäusen stammende menschliche Antikörper gegen IL-8
AU2466895A (en) 1995-04-28 1996-11-18 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6506770B1 (en) 1996-06-06 2003-01-14 Anormed, Inc. Antiviral compounds
US5801030A (en) 1995-09-01 1998-09-01 Genvec, Inc. Methods and vectors for site-specific recombination
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
CA2273194C (fr) 1996-12-03 2011-02-01 Abgenix, Inc. Mammiferes transgeniques possedant des loci de genes d'immunoglobuline dorigine humaine, dotes de regions vh et vk, et anticorps produits a partir de tels mammiferes
WO1998034633A1 (fr) 1997-02-11 1998-08-13 Mallinckrodt Chemical, Inc. Reacteur et procede de synthese de peptide en phase solide
CA2323525C (fr) 1998-03-30 2011-03-01 Gerald P. Murphy Applications therapeutiques et diagnostiques basees sur le role du gene cxcr-4 dans l'oncogenese
MXPA01009674A (es) 1999-03-24 2003-07-21 Anormed Inc Compuestos heterociclicos que se unen a receptores de quimiocina.
CA2389545C (fr) 1999-12-17 2010-08-31 Anormed Inc. Recepteur de chemokine liant des composes heterocycliques
AU5811001A (en) 2000-05-09 2001-11-20 Univ British Columbia Cxcr4 antagonist treatment of hematopoietic cells
CA2412436C (fr) 2000-06-05 2013-05-21 The Trustees Of Columbia University In The City Of New York Identification et utilisation des cellules progenitrices endotheliales derivees de la moelle osseuse, destinees a ameliorer la fonction du myocarde apres un accident ischemique
CN102302493B (zh) * 2001-07-31 2015-08-12 健赞股份有限公司 活化祖细胞/干细胞的方法
AU2002324723B2 (en) 2001-08-16 2007-10-25 The Trustees Of The University Of Pennsylvania Synthesis and use of reagents for improved DNA lipofection and/or slow release pro-drug and drug therapies
US20030199464A1 (en) * 2002-04-23 2003-10-23 Silviu Itescu Regeneration of endogenous myocardial tissue by induction of neovascularization
US7683036B2 (en) 2003-07-31 2010-03-23 Regulus Therapeutics Inc. Oligomeric compounds and compositions for use in modulation of small non-coding RNAs
WO2007002372A2 (fr) 2005-06-24 2007-01-04 Regents Of The University Of Minnesota Utilisation de cytosine désaminases afin de réduire le transfert de rétroelements des porcs à l’homme
ES2539616T3 (es) 2005-10-18 2015-07-02 Precision Biosciences Meganucleasa diseñada racionalmente con afinidad de formación de dímeros alterada
EP1995316A1 (fr) 2007-05-25 2008-11-26 Qiagen GmbH Procédé de purification de cellules préservant lesdites cellules, obtention de cellules et transfection de cellules
EP2009095A1 (fr) 2007-06-28 2008-12-31 Innovalor AG Procédé de génération de céllules sensibles au glucose
AU2008318430A1 (en) 2007-10-31 2009-05-07 Precision Biosciences, Inc. Rationally-designed single-chain meganucleases with non-palindromic recognition sequences
PE20100362A1 (es) 2008-10-30 2010-05-27 Irm Llc Derivados de purina que expanden las celulas madre hematopoyeticas
EP2270025A1 (fr) 2009-06-29 2011-01-05 Centre National pour la Recherche Scientifique (CNRS) Synthèse de peptide en phase solide d'alcools peptidiques
US20110197290A1 (en) 2010-02-11 2011-08-11 Fahrenkrug Scott C Methods and materials for producing transgenic artiodactyls
JP2014509195A (ja) 2011-02-25 2014-04-17 リコンビネティクス・インコーポレイテッド 遺伝子改変動物、およびそれを作製する方法
US9388212B2 (en) 2013-02-21 2016-07-12 Chemical & Biopharmaceutical Laboratories Of Patras S.A. Solid phase peptide synthesis via side chain attachment
US8697359B1 (en) 2012-12-12 2014-04-15 The Broad Institute, Inc. CRISPR-Cas systems and methods for altering expression of gene products
EP2946008A4 (fr) * 2013-01-15 2016-07-20 Ohio State Innovation Foundation Méthodes de mobilisation de cellules souches hématopoïétiques
EP2961828A4 (fr) * 2013-02-28 2016-08-03 Harvard College Procédés et compositions pour mobiliser des cellules souches
US9169287B2 (en) 2013-03-15 2015-10-27 Massachusetts Institute Of Technology Solid phase peptide synthesis processes and associated systems
WO2018085574A2 (fr) * 2016-11-02 2018-05-11 Washington University Compositions comprenant un inhibiteur d'intégrine et des agents qui interagissent avec une chimiokine et leurs procédés d'utilisation
US10058573B1 (en) * 2017-12-06 2018-08-28 Magenta Therapeutics, Inc. Dosing regimens for the mobilization of hematopoietic stem cells

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005000333A1 (fr) * 2003-06-05 2005-01-06 Anormed Inc. Procedes de mobilisation de cellules progenitrices/souches
US20060035829A1 (en) * 2004-08-13 2006-02-16 Anormed Inc. Chemokine combinations to mobilize progenitor/stem cells
WO2007047882A2 (fr) * 2005-10-18 2007-04-26 Caritas St. Elizabeth Medical Center Of Boston, Inc. Combinaison d'un antagoniste cxcr4 et d'un morphogene pour l'accroissement de l'angiogenese
WO2008017025A2 (fr) * 2006-08-02 2008-02-07 Genzyme Corporation Thérapie combinée
WO2008019371A1 (fr) * 2006-08-07 2008-02-14 Genzyme Corporation Thérapie combinée
WO2017147610A1 (fr) * 2016-02-26 2017-08-31 President And Fellows Of Harvard College Cellules souches hématopoïétiques à haut potentiel de prise de greffe

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
PELUS LOUIS M ET AL,, THE COMBINATION OF AMD3100 PLUS GROBETA RAPIDLY MOBILIZES HEMATOPOIETIC STEM CELLS WITH ENHANCED HOMING, ADHESION AND SURVIVAL PROPERTIES, 31 October 2008 (2008-10-31) *
PELUS LOUIS M ET AL,, THE CXCR4 ANTAGONIST AMD3100 AND THE CXCR2 AGONIST GRO BETA SYNERGISTICALLY MOBILIZE HEMATOPOETIC STEM CELLS (HSC) WITH SHORT AND LONG TERM REPOPULATING ACTIVITY, 1 November 2006 (2006-11-01) *

Also Published As

Publication number Publication date
IL275077A (en) 2020-07-30
CN111712262A (zh) 2020-09-25
WO2019113375A2 (fr) 2019-06-13
JP2024023226A (ja) 2024-02-21
AU2018378804B2 (en) 2025-10-02
KR20200096942A (ko) 2020-08-14
WO2019113375A3 (fr) 2019-07-18
EP3720494A2 (fr) 2020-10-14
IL315735A (en) 2024-11-01
IL275077B1 (en) 2024-10-01
SG11202004913TA (en) 2020-06-29
MX2024004652A (es) 2024-05-07
MX2020005878A (es) 2020-10-07
AU2018378804A1 (en) 2020-06-11
BR112020011186A2 (pt) 2020-11-17
CO2020007275A2 (es) 2020-07-31
JP2021505172A (ja) 2021-02-18
CA3083783A1 (fr) 2019-06-13

Similar Documents

Publication Publication Date Title
US20250295698A1 (en) Dosing regimens for the mobilization of hematopoietic stem cells
US20250032549A1 (en) Dosing regimens for the mobilization of hematopoietic stem and progenitor cells
IL275077B2 (en) Dosing regimens for mobilization of hematopoietic stem and progenitor cells.
JP7412341B2 (ja) 造血幹細胞および前駆細胞の増幅のための組成物および方法
US11260079B2 (en) Dosing regimens for the mobilization of hematopoietic stem and progenitor cells
US20220401481A1 (en) Dosing regimens for the mobilization of hematopoietic stem and progenitor cells
IL297690A (en) Methods and compositions for transducing hematopoietic stem and progenitor cells in vivo
US20190343885A1 (en) Compositions and methods for hematopoietic stem and progenitor cell transplant therapy
US20240189387A1 (en) Dosing regimens for hematopoietic stem cell mobilization for stem cell transplants in multiple myeloma patients
US20230414565A1 (en) Compositions and methods for treating hematological malignancies
US20210379113A1 (en) Methods for hematopoietic stem and progenitor cell transplant therapy
US20200338132A1 (en) Compositions and methods for the expansion of hematopoietic stem and progenitor cells and treatment of inherited metabolic disorders
JPWO2020092694A5 (fr)